셀렉티스 (CLLS) 주가

셀렉티스(CLLS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.53 (+4.79%), 시가총액 $0.36B, 52주 최저~최고 $1.33 ~ $5.35.

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatm

핵심 지표

• 현재가: $1.53 (+4.79%)
• 시가총액: $0.36B
• 52주 최저~최고: $1.33 ~ $5.35
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

셀렉티스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

셀렉티스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 3.8

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 5.95
• 순이익률: -0.90%
• 영업이익률: -3.33%

자주 묻는 질문